A convergent uptake route for peptide- and polymer-based nucleotide delivery systems (2015)
Sequence: Stearyl-AGYLLGKLLOOLAAAALOOLL-NH2
| Experiment Id | EXP000917 |
|---|---|
| Paper | A convergent uptake route for peptide- and polymer-based nucleotide delivery systems |
| Peptide | PepFect 14 (PF14) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | not reported (complexed at CR3 for plasmid delivery per methods) |
| Rna Concentration | 0.5–1 µg pGL3 (per well; 24-well plate) |
| Mixing Ratio | CR3 (+/−) for plasmid delivery (reported for PF14) |
| Formulation Format | noncovalent CPP:pDNA complexes |
| Formulation Components | PF14 peptide + pGL3 luciferase plasmid DNA; uptake inhibited by SCARA inhibitors; reduced delivery after SCARA3/5 knockdown; increased delivery after SCARA3/5 overexpression |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa cells |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro reporter expression (luciferase) |
| Output Value | Luciferase delivery inhibited by SCARA inhibitors; reduced by SCARA3/5 siRNA; increased by SCARA3/5 overexpression |
| Output Units | |
| Output Notes | Multiple lines of evidence for SCARA-mediated uptake (pharmacological inhibitors; siRNA knockdown; overexpression). |
| Toxicity Notes | |
| Curation Notes |